NSF award 2503896 · University of Alabama Tuscaloosa

Engineering biomimetic environments to study innate immune cell-mediated resistance to therapy in brain metastatic breast cancer

Final report due

29 December 2029

in 1,168 days · The award ends on 31 August 2029.

GrantClerk is a private service. We are not NSF or any government agency.

Dates this award owes

NSF emails you about this too.

Decide about an extension3 May 2029in 928 days
award ending 2029-08-31 · Research.gov
This one is ours, not NSF’s.
Extension request17 Jul 2029in 1003 days
award ending 2029-08-31 · Research.gov
PAPPG 24-1: “at least 45 days prior to the end date”
No-cost extension notice21 Aug 2029in 1038 days
award ending 2029-08-31 · Research.gov
PAPPG 24-1: “at least ten calendar days prior to the end date”
Final report due29 Dec 2029in 1168 days
award ending 2029-08-31 · Research.gov
PAPPG 24-1: “no later than 120-days following the end date of the award”
Project outcomes report due29 Dec 2029in 1168 days
award ending 2029-08-31 · Research.gov
PAPPG 24-1: “no later than 120 days following the end date”
Award is closed out29 Dec 2029in 1168 days
award ending 2029-08-31 · Research.gov
PAPPG 24-1: “financially closed out 120 days after their expiration date”

Annual report dates come from the budget period on your award notice. That date is not public, so it is not shown here.

How we got this date

NSF lists this award's end date as 31 August 2029.
NSF rules say the final report is due no later than 120 days after that.
So the final report is due by 29 December 2029.

Read the rule on Research.gov

Get a note before each report date

Add this award to your desk. We email you before each date and keep the dates in one place.

Renews each year until you cancel. Cancel any time from your account.

Already a member? Sign in

Award card

Award number: 2503896
Period of support: 1 Sep 2025 – 31 Aug 2029
Amount: $360,000
Awardee: University of Alabama Tuscaloosa, Tuscaloosa, AL
Program: Engineering of Biomed Systems
Directorate: ENG

Abstract

Most deaths from breast cancer occur because the cancer becomes metastatic and spreads to one or more organs. Brain metastatic breast cancer (BMBC) is very aggressive. The prognosis for patients with brain metastases from breast cancer remains poor, often because of resistance to treatment. The environment of BMBC includes tumor cells, immune cells and extracellular matrix (ECM), which is the network of molecules…

Is this right?

We copy this from the public NSF award record. Your award notice and NSF always win. If a date looks wrong, check Research.gov.